We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.

MNTA
Momenta Pharmaceuticals Inc.
NasdaqGS
People also watch : ALNY ACOR THRX NBIX MDCO
11.40 -0.01 (-0.09%)

After hours: 11.400.00 (0.00%) as of 4:58 PM EDT

Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • Max
1d
Prev Close 11.41
Open 11.49
Bid 7.12 x 100
Ask 15.99 x 300
52wk Range 7.86 - 23.89
Day's Range 11.36 - 11.57
Volume 220,926
Avg Vol (3m) 511,006
As of 4:00 PM EDT. Market closed.
  • Capital Cube 15 days ago

    Momenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : MNTA-US : June 27, 2016

    Click here to see latest analysis*Disclaimer : This is as of previous day’s closing price.Technical IndicatorsBelow is a quick look at 5 technical indicators for Momenta Pharmaceuticals, Inc.. More studies are available on the Technical Chart.IndicatorSignalClosing Price above/below 50 Day Moving AverageBearishClosing Price above/below 200 Day Moving AverageBearish50 Day Moving Average above/below 200 Day Moving […] (Read more...) The post Momenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : MNTA-US : June 27, 2016 appeared first on CapitalCube.

  • Bloomberg 22 days ago

    Visium Insider-Trading Scheme Brought Down by Tip on Mismarking

    What turned into one of the biggest insider-trading cases at a hedge fund in recent years started out as something entirely different: a probe into whether some portfolio managers at Visium Asset Management ...

  • TheStreet.com 26 days ago

    Visium Hedge Fund Partner Charged in Insider Trading Case

    After a Supreme Court setback to the federal crackdown on insider trading, U.S. Attorney Preet Bharara signals his intent to forge ahead with new indictments reminiscent of the SAC case.

  • Reuters 26 days ago

    Visium's Valvani charged with insider trading on FDA leaks

    A Manhattan hedge fund manager was charged on Wednesday with trading on confidential tips about drug approvals, in one of the biggest insider trading cases since a 2014 court ruling made it harder for U.S. prosecutors to pursue them. U.S. Attorney Preet Bharara in Manhattan accused Sanjay Valvani of Visium Asset Management LP of fraudulently making $25 million by gaining advance word about U.S. Food and Drug Administration approvals of generic drug applications.

  • Motley Fool 2 months ago

    Momenta Pharmaceuticals: Waiting for Fewer Injections

    Sales of Glatopa trudge along, but the big opportunity is for the three-times-a-week version of the drug.

  • Capital Cube 2 months ago

    Momenta Pharmaceuticals, Inc. :MNTA-US: Earnings Analysis: Q1, 2016 By the Numbers

    Click here to see latest analysisMomenta Pharmaceuticals, Inc. reports financial results for the quarter ended March 31, 2016.We analyze the earnings along side the following peers of Momenta Pharmaceuticals, Inc. – Biogen Inc., Bristol-Myers Squibb Company, Baxter International Inc., Amgen Inc., Johnson & Johnson and Novartis AG Sponsored ADR (BIIB-US, BMY-US, BAX-US, AMGN-US, JNJ-US and […] (Read more...) The post Momenta Pharmaceuticals, Inc. :MNTA-US: Earnings Analysis: Q1, 2016 By the Numbers appeared first on CapitalCube.

  • Thomson Reuters StreetEvents 2 months ago

    Edited Transcript of MNTA earnings conference call or presentation 3-May-16 1:00pm GMT

    Q1 2016 Momenta Pharmaceuticals Inc Earnings Call

  • Associated Press 2 months ago

    Momenta reports 1Q loss

    On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 35 cents. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

  • Capital Cube 3 months ago

    Momenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : MNTA-US : April 21, 2016

    Click here to see latest analysis*Disclaimer : This is as of previous day’s closing price.Technical IndicatorsBelow is a quick look at 5 technical indicators for Momenta Pharmaceuticals, Inc.. More studies are available on the Technical Chart.IndicatorSignalClosing Price above/below 50 Day Moving AverageBearishClosing Price above/below 200 Day Moving AverageBearish50 Day Moving Average above/below 200 Day Moving […] (Read more...) The post Momenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : MNTA-US : April 21, 2016 appeared first on CapitalCube.

  • Capital Cube 3 months ago

    Momenta Pharmaceuticals, Inc. – Value Analysis (NASDAQ:MNTA) : April 8, 2016

    Click here to see latest analysisCapitalcube gives Momenta Pharmaceuticals, Inc. a score of 29.Our analysis is based on comparing Momenta Pharmaceuticals, Inc. with the following peers – Biogen Inc., Bristol-Myers Squibb Company, Baxter International Inc., Teva Pharmaceutical Industries Limited Sponsored ADR, Amgen Inc., Johnson & Johnson, Pfizer Inc., Novartis AG Sponsored ADR, Merck & Co., […] (Read more...) The post Momenta Pharmaceuticals, Inc. – Value Analysis (NASDAQ:MNTA) : April 8, 2016 appeared first on CapitalCube.